Veru Inc. (NASDAQ:VERU - Get Free Report)'s share price crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.59 and traded as high as $0.61. Veru shares last traded at $0.58, with a volume of 1,232,223 shares changing hands.
Veru Stock Performance
The stock has a market cap of $91.47 million, a price-to-earnings ratio of -2.59 and a beta of -0.75. The company's 50 day simple moving average is $0.58 and its 200 day simple moving average is $0.59.
Veru (NASDAQ:VERU - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.01. Sell-side analysts predict that Veru Inc. will post -0.22 EPS for the current year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of the business. Atria Investments Inc grew its holdings in shares of Veru by 21.2% during the 4th quarter. Atria Investments Inc now owns 171,707 shares of the company's stock valued at $112,000 after acquiring an additional 30,043 shares in the last quarter. JPMorgan Chase & Co. boosted its position in Veru by 337.4% during the fourth quarter. JPMorgan Chase & Co. now owns 255,782 shares of the company's stock worth $166,000 after purchasing an additional 197,307 shares during the period. Geode Capital Management LLC boosted its position in Veru by 2.0% during the fourth quarter. Geode Capital Management LLC now owns 2,997,751 shares of the company's stock worth $1,950,000 after purchasing an additional 57,611 shares during the period. Wells Fargo & Company MN boosted its position in Veru by 37.1% during the fourth quarter. Wells Fargo & Company MN now owns 75,512 shares of the company's stock worth $49,000 after purchasing an additional 20,430 shares during the period. Finally, Envestnet Asset Management Inc. boosted its holdings in Veru by 23.0% during the fourth quarter. Envestnet Asset Management Inc. now owns 406,755 shares of the company's stock valued at $265,000 after acquiring an additional 75,997 shares during the period. Hedge funds and other institutional investors own 47.16% of the company's stock.
Veru Company Profile
(
Get Free Report)
Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.
Read More
Before you consider Veru, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Veru wasn't on the list.
While Veru currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
